Arcus Biosciences, INC 8-K filings

NYSE

30 Jan 2024

RCUS

8-K: Gilead Increases Stake in Arcus Biosciences with $320 Million Investment, Streamlining Cancer Drug Development

Gilead Sciences has made a $320 million equity investment in Arcus Biosciences, amending their collaboration to accelerate key cancer drug programs and increasing Gilead's ownership stake to 33%.